IGF1R and neoplasm: Gorlick, Houghton, and others have reported relative insensitivity to IGF-1R- or mTOR-targeted therapies in vitro compared to xenografts models of similar tumor types, supporting our hypothesis that extracellular mechanisms of resistance are important [108].